Compare HubSpot Inc (HUBS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs TransMedics Group Inc — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: HubSpot Inc is far larger — about 4.2× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 1,891,287). Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and TransMedics Group Inc for 24 Days on average.
| HUBS | TMDX | |
|---|---|---|
Market Cap | $11.56B | $2.74B |
Volume | 1,891,287 | 949,331 |
Sector | Technology | Health |
52-Week High | $494.58 | $150.42 |
52-Week Low | $170.39 | $61.99 |
Typical Hold Time | 78 Days | 24 Days |
Enterprise Value | $10.46B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $228.30, up 3.63% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with improving profitability, though valuation ratios remain elevated. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though risks include high P/E ratio, competitive pressures, and potential AI disruption concerns. The stock offers growth exposure with solid cash flow generation but requires monitoring of execution against ambitious margin targets.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
